|
000
| 03163nam 2200373zi 4500 |
|---|
| 001 | 9.933602 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20240222171343 |
|---|
| 006 | m o d f |
|---|
| 007 | cr mn||||||||| |
|---|
| 008 | 240207e202201##onc o f000 0 eng d |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aHP5-221/2022E-PDF |
|---|
| 245 | 00|aEvaluation of the evidence for health promotion, chronic disease and injury prevention program : |bfocus on COVID-19 activities / |cprepared by: Office of Audit and Evaluation Health Canada and the Public Health Agency of Canada. |
|---|
| 264 | 1|a[Ottawa] : |bHealth Canada and the Public Health Agency of Canada = Santé Canada et l'Agence de la santé publique du Canada, |cJanuary 2022. |
|---|
| 300 | |a1 online resource (iv, 24 pages) : |billustrations, maps |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aCover title. |
|---|
| 500 | |aIssued also in French under title: Évaluation des données probantes liées à la promotion de la santé et à la prévention des maladies chroniques et des blessures : accent sur les activités liées à la COVID-19. |
|---|
| 504 | |aIncludes bibliographical references (pages 23-24). |
|---|
| 520 | |a"The Evidence for Health Promotion, Chronic Disease and Injury Prevention Program (Evidence Program), situated within PHAC’s Health Promotion and Chronic Disease Prevention Branch (HPCDPB), is an important player in understanding the wider impact of the COVID-19 pandemic on various groups. The Evidence Program, led by the Centre for Surveillance and Applied Research (CSAR), collects and analyzes national surveillance data on maternal, child/youth, and seniors’ health; chronic diseases and conditions; injuries; health inequalities; and the associated social, behavioural, and environmental determinants of health. It also carries out research to build a strong evidence base for action on public health. The Evidence Program is responsible for providing information to a broad range of stakeholders, including government senior leadership, Special Advisory Committees, national working groups, and the Canadian public"--Executive summary, page ii. |
|---|
| 610 | 20|aPublic Health Agency of Canada. |bOffice of Audit and Evaluation. |
|---|
| 650 | 0|aHealth promotion|xGovernment policy|zCanada|xEvaluation. |
|---|
| 650 | 0|aChronic diseases|zCanada|xEvaluation. |
|---|
| 650 | 0|aPost COVID-19 condition (Disease) |xDiagnosis|zCanada. |
|---|
| 710 | 1 |aCanada. |bHealth Canada. |bOffice of Audit and Evaluation, |eissuing body. |
|---|
| 710 | 2 |aPublic Health Agency of Canada, |eissuing body. |
|---|
| 775 | 08|tÉvaluation des données probantes liées à la promotion de la santé et à la prévention des maladies chroniques et des blessures : |w(CaOODSP)9.934300 |
|---|
| 856 | 40|qPDF|s898 KB|uhttps://publications.gc.ca/collections/collection_2024/aspc-phac/HP5-221-2022-eng.pdf |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/corporate/transparency/corporate-management-reporting/evaluation/evidence-health-promotion-chronic-disease-injury-prevention-program-2022.html |
|---|